Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Rhea-AI Summary

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company focused on RNAi therapies for KRAS-driven cancers, has announced warrant exercise agreements totaling $1.8 million in gross proceeds. The agreement involves the immediate exercise of 152,106 outstanding warrants at $11.57 per share.

As part of the transaction, the company will issue new unregistered warrants to purchase up to 304,212 ordinary shares at an exercise price of $11.32 per share. These new warrants will have a 24-month term and will become exercisable following shareholder approval of increased authorized shares. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering.

Positive

• Immediate cash injection of $1.8 million to strengthen working capital
• Successful warrant exercise indicates investor confidence
• New warrants provide potential for additional future funding

Negative

• Dilutive effect from the issuance of new shares
• Additional dilution potential from new warrants (304,212 shares)
• New warrants exercise contingent on shareholder approval for share increase

News Market Reaction – SLXN

-37.88% 35.5x vol

26 alerts

-37.88% News Effect

+67.5% Peak Tracked

-39.8% Trough Tracked

-$8M Valuation Impact

$13M Market Cap

35.5x Rel. Volume

On the day this news was published, SLXN declined 37.88%, reflecting a significant negative market reaction. Argus tracked a peak move of +67.5% during that session. Argus tracked a trough of -39.8% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $13M at that time. Trading volume was exceptionally heavy at 35.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company’s ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company’s authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below).

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Silexion Therapeutics

Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able  to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact:

Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Capital Markets & IR Contact:

Arx | Capital Market Advisors
North American Equities Desk
silexion@arxadvisory.com

FAQ

How much funding did Silexion Therapeutics (SLXN) raise through warrant exercise in August 2025?

Silexion Therapeutics raised $1.8 million in gross proceeds through the exercise of warrants at $11.57 per share.

What is the exercise price of SLXN's newly issued warrants?

The new warrants have an exercise price of $11.32 per share and can purchase up to 304,212 ordinary shares.

When will Silexion's new warrants become exercisable?

The new warrants will become exercisable upon shareholder approval of increased authorized ordinary shares and will have a term of 24 months from the effective date of the Resale Registration Statement.

How will Silexion Therapeutics use the proceeds from the warrant exercise?

The company intends to use the net proceeds as working capital for general corporate purposes.

Who is the placement agent for Silexion's warrant exercise offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.